Five-Year Summary

Track our recent performance by year, region and major product group.

All figures are in US$ million unless stated otherwise

2017-18 
Constant Currency(1)
 
2017-18 
Reported(2)
 
2016-17 
Reported
2015-16
Reported 
2014-15 
Reported
2013-14
Reported 
Total Operating Revenue  7,717  7,915 6,947 6,115 5,612 5,504
Sales Revenue  7,394  7,588 6,616 5,909 5,459 5,335
R&D Investment  685  702 667 614 463 466
Profit before Income Tax Expense  2,260  2,281 1,690 1,556 1,714 1,604
Net profit after tax  1,713  1,729 1,337 1,242 1,379 1,307
Net cash inflow from Operating Activities    1,902 1,247 1,179 1,364 1,361
Capital investment    992 861 566 414 402
Return on Invested Capital (%)    25.9 24.5 26.8%(3) 31.70% 31.80%
Basic earnings per share ($)    3.822 2.937 2.689 2.923 2.701
Dividend per share ($)    1.720 1.360 1.26 1.24 1.13

(1) Constant currency removes the impact of exchange rate movements, facilitating comparability of operational performance. For further details please refer to CSL’s Financial
Statements for the Full Year ended 2018 (Directors’ Report).
(2) The Group’s reported results are in accordance with the Australian Equivalents to International Financial Reporting Standards (A-IFRS).
(3) 2016 figure includes the gain on acquisition of Novartis’ global influenza vaccine business of US$176.1 million.

 

Get our latest news in your inbox

mail@example.com
First name
Last name
Country

Thanks!

Thank you for subscribing
to the CSL newsletter